FDMT

4.31

3.86% 0.16

Handel nachbörslich: 4.31

4 D Molecular Therapeutics Inc (FDMT)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$4.15

Offen:

$4.15

24-Stunden-Volumen:

619.36K

Relative Volume:

1.08

Marktkapitalisierung:

$207.07M

Einnahmen:

$20.72M

Nettoeinkommen (Verlust:

$-100.84M

KGV:

-1.6203

EPS:

-2.66

Netto-Cashflow:

$-78.56M

1W Leistung:

+5.64%

1M Leistung:

+14.93%

6M Leistung:

-26.07%

1J Leistung:

-79.06%

1-Tages-Spanne:

$4.15

$4.40

1-Wochen-Bereich:

$3.68

$4.40

52-Wochen-Spanne:

$2.235

$28.93

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Firmenname

4 D Molecular Therapeutics Inc

Sektor

Healthcare (1166)

Branche

Biotechnology (655)

Telefon

(510) 505-2680

Adresse

5858 HORTON STREET #455, EMERYVILLE

Mitarbeiter

227

Twitter

Nächster Verdiensttermin

2024-12-13

Neueste SEC-Einreichungen

FDMT's Discussions on Twitter

Vergleichen Sie FDMT mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
FDMT 4 D Molecular Therapeutics Inc	4.31	207.07M	20.72M	-100.84M	-78.56M	-2.66
VRTX Vertex Pharmaceuticals Inc	457.03	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	547.74	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	329.77	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	545.11	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	244.32	28.51B	3.81B	-644.79M	-669.77M	-6.24

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-01-13	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2024-11-21	Eingeleitet	Morgan Stanley	Underweight
2024-09-23	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2024-04-15	Eingeleitet	Barclays	Overweight
2024-02-07	Fortgesetzt	Goldman	Buy
2023-10-26	Eingeleitet	RBC Capital Mkts	Outperform
2023-10-24	Eingeleitet	Cantor Fitzgerald	Overweight
2023-10-18	Hochstufung	Leerink Partners	Market Perform → Outperform
2023-07-05	Eingeleitet	Chardan Capital Markets	Buy
2023-01-30	Eingeleitet	BMO Capital Markets	Outperform
2022-11-18	Eingeleitet	H.C. Wainwright	Buy
2022-11-15	Hochstufung	Goldman	Neutral → Buy
2022-08-12	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2022-06-22	Eingeleitet	Jefferies	Buy
2022-01-04	Eingeleitet	SVB Leerink	Outperform
2021-01-05	Eingeleitet	BofA Securities	Buy
2021-01-05	Eingeleitet	Evercore ISI	Outperform
2021-01-05	Eingeleitet	Goldman	Neutral

Alle ansehen

4 D Molecular Therapeutics Inc Aktie (FDMT) Neueste Nachrichten

Jun 17, 2025

Cystic Fibrosis Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

Jun 17, 2025

Oligonucleotides Clinical Trial Pipeline Analysis Demonstrates 280+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - SINA HONG KONG LIMITED

Jun 17, 2025

Jun 16, 2025

Gene Therapy in Ophthalmology Market Set to Transform Vision Restoration Landscape by 2034 | Says DelveInsight - Barchart.com

Jun 16, 2025

Harbor Capital Advisors Inc. Invests $99,000 in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Jun 16, 2025

Jun 13, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Position Raised by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

Jun 13, 2025

Jun 12, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World

Jun 12, 2025

908 Devices’ (MASS) “Sell (D-)” Rating Reiterated at Weiss Ratings - Defense World

Jun 12, 2025

Organigram (TSE:OGI) Stock Price Up 2% – Should You Buy? - Defense World

Jun 12, 2025

Analysts Issue Forecasts for FDMT FY2026 Earnings - Defense World

Jun 12, 2025

Jun 11, 2025

Vivani Medical Appoints Anthony Baldor as Chief Financial Officer - The Manila Times

Jun 11, 2025

Fabry Disease Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - GlobeNewswire

Jun 10, 2025

Jun 05, 2025

4D Molecular Therapeutics Being Investigated on Behalf of 4D Molecular Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire

Jun 05, 2025

Jun 04, 2025